| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 535.90 | 73.4% |
| Total Income | 539.20 | 73.4% |
| Expenditure | 373.90 | 76.0% |
| PBT | 165.30 | 61.7% |
| Net Profit | 119.50 | 71.1% |
| OPM | 32.08% | 13.37pp |
| NPM | 22.16% | 6.70pp |
| EPS | 51.89 | 61.9% |
Sanofi India Ltd Announces 4% Growth in Net Sales & 27% Growth in Operating Profits in Q1-2025
14 May 2025 · 14 May 2025, 05:43 pm
Summary
Sanofi India Ltd has announced its financial results for the quarter ended on March 31, 2025. The Company has delivered net sales growth of 4% on a comparable basis of continuing business. The successful launch of Soliqua®, the best-in-class diabetes drug for the premix segment, continues with a steady growth. The Company was able to increase its operating profit by 27% vs Q1-2024. The improved operating profit was a result of the Company’s focus on lowering expenses through overall operating efficiencies. The Company continues to make good progress on its ‘India for India’ strategy through go-to-market initiatives, improving operating efficiency and promoting innovation.
Key Highlights
- 1
4% growth in net sales on a comparable basis of continuing business
- 2
27% growth in operating profits vs Q1-2024
- 3
Successful launch of Soliqua®, the best-in-class diabetes drug for the premix segment
- 4
Company's focus on lowering expenses through overall operating efficiencies
- 5
Good progress on ‘India for India’ strategy
Management Comments
Rachid Ayari
The Company has delivered a strong first quarter performance reflecting Sanofi’s successful strategy for India. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its best-in-class innovative products in India.
Informational and educational content only. Not investment advice.